Every 10-Q that Gentex Corp (GNTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNTX filings page.
Gentex Corporation reported Q2 2026 net sales of $651,299,705, down 1% from Q2 2025, while net income attributable to Gentex rose to $114,689,417 and diluted EPS to $0.54 from $0.43. Consolidated gross margin improved to 37.0%, helped by approximately $18 million of IEEPA tariff reimbursements and favorable product mix, partly offset by commodity cost increases and lower automotive volumes.
For the six months ended June 30, 2026, net sales were $1,326,742,831 and net income attributable to Gentex was $213,144,560, with diluted EPS of $1.00. Operating cash flow reached $321,663,680, supporting $137,873,659 of share repurchases, $51,409,775 of dividends, and $36,237,437 of capital spending. Cash and cash equivalents were $233,444,229 with no borrowings under the $350 million revolving credit facility and $3,706,980 of short-term debt.
Automotive Products remained the largest segment with Q2 sales of $560,201,415 and a 10% decline in total auto-dimming mirror units to 10,416 thousand, driven by weaker international interiors. Premium Audio Products revenue increased to $51,687,407 and Other segment revenue to $39,410,883, reflecting contributions from the 2025 VOXX and BioConnect acquisitions. Year‑to‑date results include a $2.8 million impairment of Vaporsens in‑process R&D, $12.2 million of impairments on two technology investments, and a $5.1 million increase in credit loss allowances on loans to technology investees.
Gentex Corporation reported higher first-quarter 2026 results, helped by its VOXX acquisition and steady core operations. Net sales rose to $675.4 million from $576.8 million, a 17% increase, with VOXX contributing $88.6 million and core Gentex revenue edging up despite lower global light vehicle production.
Gross margin improved to 33.8%, supported by operational efficiencies and better product mix, partly offset by tariffs and commodity costs. GAAP net income attributable to Gentex increased to $98.5 million from $94.9 million, and diluted EPS rose to $0.46 from $0.42. Non‑GAAP adjusted diluted EPS was $0.48, versus $0.43 a year earlier.
The company recorded a $2.8 million impairment on Vaporsens in‑process R&D and a $2.7 million impairment on a technology investment, along with a $2.2 million increase in credit loss allowances on loans to technology investees. Gentex ended the quarter with $164.8 million in cash and cash equivalents and generated $137.1 million in operating cash flow.
Gentex Corporation (GNTX) filed its Q3 2025 Form 10‑Q, reporting steady top‑line growth with net sales of $655,236,055, up from $608,525,777 a year ago. Quarterly net income was $100,967,910, and diluted EPS was $0.46.
For the first nine months, sales reached $1,889,867,355 with net income of $291,881,539. Operating cash flow was strong at $461,627,573, while the company invested in capacity and deals, including the April 1 consolidation of VOXX. Gentex recognized $8.4 million in other‑than‑temporary impairment charges on technology investments and increased its credit loss allowance by $4.8 million. The company amended its unsecured revolver to $350.0 million on October 2, 2025. It returned capital via dividends of $0.12 per share in Q3 and repurchased $230,450,683 of stock year‑to‑date. Cash and cash equivalents were $178,589,422 at quarter‑end, and shares outstanding were 218,942,919 as of October 24, 2025.
Gentex reported consolidated net sales of $657.9 million for the quarter ended June 30, 2025, up 15% from $572.9 million a year earlier, driven largely by the April 1, 2025 acquisition of VOXX which contributed $78.8 million of revenue. Consolidated gross profit rose to $225.3 million, and consolidated income from operations was $118.5 million. Net income attributable to Gentex was $96.0 million (diluted EPS $0.43), versus $86.0 million (EPS $0.37) in the comparable quarter.
Cash and cash equivalents decreased to $119.8 million from $233.3 million at year-end 2024 after investing activity, acquisition payments and share repurchases. Operating cash flow provided $314.6 million in the six months ended June 30, 2025. The company completed the VOXX acquisition for approximately $148.3 million in cash (total consideration, net $187.7 million including fair value of prior holdings) and made other biometric-related acquisitions; integration costs, severance and a $6.2 million impairment were recorded in the quarter.